Vutrisiran
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 123 publications
Efficacy of Suppression of Serum Transthyretin With Patisiran and Vutrisiran in Variant ATTR Amyloidosis: An Observational Crossover Study.
Journal: Circulation
Published: February 02, 2026
Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study.
Journal: European journal of heart failure
Published: January 21, 2026
Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.
Journal: Current problems in cardiology
Published: January 07, 2026
Hidden overlap between heart failure with preserved ejection fraction and transthyretin amyloid cardiomyopathy: Why it matters and how to avoid missing it.
Journal: International journal of cardiology
Published: December 22, 2025
Precision medicine with pioneering RNAi therapeutics in ATTR amyloidosis: from bench to bedside.
Journal: European journal of internal medicine
Published: December 20, 2025
Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A.
Journal: Neurology and therapy
Published: December 05, 2025
Class-Specific Adverse Events of Patients Treated with Small Interfering RNA Therapeutics: A Disproportionality Analysis of the United States Food and Drug Administration Adverse Event Reporting System Database Based on the MY FAERS Platform.
Journal: Nucleic acid therapeutics
Published: November 22, 2025
Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials.
Journal: Therapeutic advances in cardiovascular disease
Published: November 12, 2025
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.
Journal: Circulation
Published: November 10, 2025
Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.
Journal: Journal of the American College of Cardiology
Published: October 31, 2025
Clinical and radiological stabilization following vutrisiran treatment in transthyretin leptomeningeal amyloidosis: a case report.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: October 29, 2025
Last Updated: 04/28/2026